Revive Therapeutics Provides Update on the Psilocybin

TORONTO, Sept. 16, 2022 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences firm centered on the analysis and growth of therapeutics for medical wants and uncommon problems, is happy to offer an replace on the Company’s Phase I/II medical research of oral psilocybin in the remedy of methamphetamine use dysfunction and the growth of its proprietary oral psilocybin skinny movie strip product.

“We continue to focus on building a specialty psilocybin-based product pipeline to treat mental illness, substance abuse and neurological disorders. We intend to advance the development of our oral psilocybin thin film strip product for these indications. In parallel, we are working on our first clinical study evaluating oral psilocybin in the treatment of methamphetamine use disorder to validate its use in substance abuse indications. The clinical data from this study will be used to support late-stage clinical trials with our oral psilocybin thin film strip product,” mentioned Derrick Welsh, COO of Psilocin Pharma, a division of Revive.

Oral Psilocybin for Methamphetamine Use Disorder

The Company is at present evaluating the use of oral psilocybin as a possible remedy for methamphetamine use dysfunction with the University of Wisconsin-Madison. Under an investigator-initiated IND, led by Dr.’s Christopher Nicholas and Paul Hutson, the Phase I/II medical research (the “Study”) to judge the security and feasibility of psilocybin in adults with methamphetamine use dysfunction obtained each FDA and Institutional Review Board approval. The Study is being carried out at the University of Wisconsin-Madison, School of Medicine and Public Health and School of Pharmacy.

The medical information that’s generated from the Study will present proprietary and helpful data on the security, efficacy and dosing of oral psilocybin to assist future pivotal FDA medical research for the Company’s proposed oral psilocybin skinny movie strip product. In addition, the Company can have unique entry to key mental property from this research to assist growth, regulatory and business initiatives.

Oral Psilocybin Thin Film Strip Product

The Company has initiated the product growth program underneath a feasibility settlement with LTS Lohmann Therapie-Systeme AG, a pacesetter in pharmaceutical oral skinny movies, to develop and manufacture a proprietary oral psilocybin skinny movie strip product for psychological sickness, substance abuse and neurological problems. Prototypes of the oral psilocybin skinny movie strip product have been developed and are being optimized to be used in upcoming IND-enabling research. The Company expects to conduct a first-in-human medical research in 2023.

About Revive Therapeutics Ltd.

Revive is a life sciences firm centered on the analysis and growth of therapeutics for infectious illnesses and uncommon problems, and it’s prioritizing drug growth efforts to reap the benefits of a number of regulatory incentives awarded by the FDA akin to Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential remedy of infectious illnesses, with an preliminary focus on extreme influenza and COVID-19. With its acquisition of Psilocin Pharma Corp., Revive is advancing the growth of Psilocybin-based therapeutics in varied illnesses and problems. Revive’s cannabinoid pharmaceutical portfolio focuses on uncommon inflammatory illnesses and the firm was granted FDA orphan drug standing designation for the use of Cannabidiol (CBD) to deal with autoimmune hepatitis (liver illness) and to deal with ischemia and reperfusion harm from organ transplantation. For extra data, go to www.ReviveThera.com.

For extra data, please contact:

Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: [email protected]
Website: www.revivethera.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts duty for the adequacy or accuracy of this launch.

Cautionary Statement

This press launch comprises ‘forward-looking information’ inside the which means of relevant Canadian securities laws. These statements relate to future occasions or future efficiency. The use of any of the phrases “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and related expressions and statements referring to issues that aren’t historic info are supposed to establish forward-looking data and are primarily based on Revive’s present perception or assumptions as to the consequence and timing of such future occasions. Forward trying data on this press launch consists of data with respect to the the Company’s cannabinoids, psychedelics and infectious illnesses applications. Forward-looking data relies on affordable assumptions which were made by Revive at the date of the data and is topic to recognized and unknown dangers, uncertainties, and different components which will trigger precise outcomes or occasions to vary materially from these anticipated in the forward-looking data. Given these dangers, uncertainties and assumptions, you shouldn’t unduly rely on these forward-looking statements. The forward-looking data contained on this press launch is made as of the date hereof, and Revive just isn’t obligated to replace or revise any forward-looking data, whether or not on account of new data, future occasions or in any other case, besides as required by relevant securities legal guidelines. The foregoing statements expressly qualify any forward-looking data contained herein. Reference is made to the danger components disclosed underneath the heading “Risk Factors” in the Company’s annual MD&A for the fiscal yr ended June 30, 2021, which has been filed on SEDAR and is out there underneath the Company’s profile at www.sedar.com.